Understanding Benzo Effects: A Comprehensive Guide for Healthcare Professionals

Benzodiazepines are a class of medications acting on benzodiazepine receptors within the central nervous system. Critical in managing various conditions, these drugs, including alprazolam, clobazam, and chlordiazepoxide, are FDA-approved and widely utilized, representing a significant portion of emergency department visits in the US due to seizure activity. Their applications extend beyond seizures to encompass insomnia, acute status epilepticus, amnesia induction, agitation, anxiety, and spastic disorders. A deep understanding of benzodiazepine pharmacology is paramount for creating tailored treatment strategies, optimizing therapeutic outcomes, and minimizing potential adverse reactions, ensuring patient safety and effective care. This article provides a detailed exploration of benzodiazepine effects, covering indications, mechanisms of action, administration guidelines, adverse effects, contraindications, toxicology, and essential monitoring practices in clinical settings. The crucial role of interprofessional healthcare teams in maximizing expertise and delivering safe, patient-centered care in benzodiazepine management is also emphasized.

Objectives:

Distinguish between different benzodiazepines, recognizing their distinct pharmacological profiles, dosages, and potential side effects to better understand their unique Benzo Effects.
Develop individualized treatment plans, adjusting benzodiazepine dosages based on specific patient needs and responses to optimize therapeutic benzo effects.
Choose appropriate monitoring techniques to guarantee the safe and effective application of benzodiazepines, including consistent evaluation of therapeutic response and possible adverse benzo effects.
Work together within an interprofessional healthcare team to exchange knowledge, discuss patient cases, and ensure a comprehensive approach to managing benzo effects and overall benzodiazepine therapy.

Access free multiple choice questions on this topic.

Indications for Benzodiazepine Use

Benzodiazepines exert their therapeutic benzo effects by interacting with specific receptors in the central nervous system (CNS). These medications are vital for managing seizure emergencies, accounting for a notable percentage of emergency room visits in the United States annually. Clinically, benzodiazepines are prescribed for a wide array of conditions. These include insomnia, acute status epilepticus, inducing amnesia for procedures, managing agitation and anxiety, and treating spastic and seizure disorders. Furthermore, the off-label use of benzodiazepines is common in psychiatry, addressing conditions such as Tourette syndrome, delirium, delirium tremens, various sleep disorders, and medication-induced movement abnormalities like tremors, tics, tardive dyskinesia, and chorea.[1][[2]](#article-18220.r2]

FDA-Approved Indications

Several benzodiazepines have received FDA approval for specific uses, primarily in the management of anxiety, seizures, and alcohol withdrawal. These FDA-approved benzo effects highlight their critical role in specific clinical scenarios:

Chlordiazepoxide: Primarily indicated for managing alcohol withdrawal syndrome, leveraging its benzo effects to alleviate withdrawal symptoms.[4]
Clonazepam: Approved for treating panic disorder and agoraphobia, utilizing its anxiolytic benzo effects. [[3]](#article-18220.r3] It is also effective in treating myoclonic and absence seizures, demonstrating its anticonvulsant benzo effects.[[6]](#article-18220.r6]
Diazepam: Used in alcohol withdrawal management, similar to chlordiazepoxide in its benzo effects on withdrawal symptoms.[[7]](#article-18220.r7] Rectal diazepam is also indicated for managing febrile seizures in children, providing rapid anticonvulsant benzo effects.[8]
Flurazepam: Indicated for insomnia treatment, leveraging its sedative benzo effects to promote sleep.[[9]](#article-18220.r9]
Midazolam: Used for convulsive status epilepticus and procedural sedation, highlighting its rapid-acting sedative and anticonvulsant benzo effects. It is also utilized for sedation in mechanically ventilated patients in intensive care settings.[[11]](#article-18220.r11]
Quazepam: Primarily indicated for chronic insomnia in adults, offering long-acting sedative benzo effects for sleep maintenance.[[13]](#article-18220.r13]
Triazolam: Primarily indicated for sleep-onset insomnia, known for its short-acting sedative benzo effects to aid in falling asleep.
Remimazolam: Approved by the FDA in 2020 for short-term procedural sedation, offering rapid onset and offset of sedative benzo effects.[14]

Mechanism of Action: How Benzo Effects Occur

Benzodiazepines’ therapeutic benzo effects are mediated through their interaction with benzodiazepine receptors in the CNS. These receptors are integral components of the gamma-aminobutyric acid type A (GABA-A) receptor complex, a protein structure forming a chloride channel across neuronal membranes. The GABA-A receptor is composed of five transmembrane subunits: two alpha, two beta, and one gamma. GABA, an inhibitory neurotransmitter, binds to receptor sites formed by the extracellular portions of alpha and beta subunits. Benzodiazepines, on the other hand, bind to a separate site located on the extracellular portions of alpha and gamma subunits.

Image: Illustration depicting the GABA-A receptor and benzodiazepine binding site, crucial for understanding benzo effects.

Upon benzodiazepine binding, a conformational change occurs in the central pore of the GABA-A receptor, facilitating the influx of chloride ions into the neuron. This chloride influx leads to neuronal hyperpolarization, resulting in CNS depression, the primary mechanism behind many benzo effects.[15] Benzodiazepines enhance the frequency of GABA-A receptor chloride channel opening in the presence of GABA. Critically, benzodiazepines have minimal to no effect on GABA-A receptor function in the absence of GABA, highlighting their modulatory rather than direct agonist action.[[16]](#article-18220.r16] This GABA-dependent mechanism contributes to the relatively safer profile of benzodiazepines compared to other CNS depressants, but understanding the nuances of these benzo effects is still vital for safe clinical use.

Pharmacokinetics of Benzodiazepines

Understanding the pharmacokinetics is crucial for predicting the onset, duration, and intensity of benzo effects.

Absorption: Oral benzodiazepines are generally well absorbed from the gastrointestinal tract, with the exception of clorazepate, which requires decarboxylation in gastric juice before absorption. Intramuscular (IM) absorption varies; diazepam and chlordiazepoxide absorption is slow, while lorazepam and midazolam are absorbed more rapidly. Intravenous (IV) administration results in quick distribution to the brain and CNS. Midazolam, highly lipophilic, rapidly crosses the blood-brain barrier, leading to fast onset of clinical benzo effects.

Distribution: Benzodiazepines and their active metabolites exhibit high plasma protein binding. Binding rates vary: approximately 70% for alprazolam, 85% for clonazepam, and 99% for diazepam. Cerebrospinal fluid concentrations roughly mirror free drug concentrations in plasma. Diazepam is known for rapid redistribution, affecting its duration of benzo effects.

Metabolism: Benzodiazepine metabolism primarily occurs in three phases. Phase one involves N-desalkylation, often producing active metabolites, except for triazolam, alprazolam, and midazolam. Phase two involves hydroxylation, typically yielding active derivatives. Phase three is glucuronide conjugation. Hepatic CYP3A4 and CYP2C19 enzymes extensively metabolize most benzodiazepines. Lorazepam is an exception, undergoing direct glucuronidation without cytochrome P450 involvement, making it suitable for patients with hepatic dysfunction due to its predictable benzo effects.[[17]](#article-18220.r17] Remimazolam is metabolized to CNS7054, a metabolite with negligible hypnotic activity, contributing to its shorter duration of benzo effects.[[18]](#article-18220.r18]

Elimination: Renal excretion is the primary elimination route for benzodiazepines and their metabolites. Diazepam generates active metabolites like oxazepam, temazepam, and desmethyldiazepam, prolonging its overall benzo effects. Elimination half-lives are extended in elderly patients and those with renal dysfunction, impacting the duration and accumulation of benzo effects.[[19]](#article-18220.r19]

Administration Guidelines for Benzodiazepines

Available Dosage Forms and Strengths

Benzodiazepines are commonly administered orally and intravenously. Other routes include rectal, intranasal, and intramuscular, chosen based on clinical needs. Intranasal or IM routes are useful for seizing patients when IV or oral access is challenging. Rectal administration in pediatrics is an option for seizure cessation before IV access is established.

Administering benzodiazepines involves incremental dosing until desired benzo effects, such as sedation, seizure cessation, or anxiolysis, are achieved. IV administration may take 3-5 minutes to reach sufficient CNS drug concentrations for desired benzo effects. Allow sufficient time between doses to prevent over-sedation.

Availability of resuscitation and airway management equipment is crucial during benzodiazepine administration. Equipment may include various airway devices and intubation capabilities, depending on emergency service provider training. Diazepam milligram equivalency can be used for dose conversion estimations.[[20]](#article-18220.r20]

Adult Dosage Considerations

Dosage varies significantly among benzodiazepines and indications. Understanding these nuances is crucial for achieving desired therapeutic benzo effects while minimizing risks.

Alprazolam: For generalized anxiety disorder, start with 0.25 to 0.5 mg three times daily, increasing every 3-4 days up to 4 mg daily. Panic disorders may require 1 to 4 mg daily. Use the lowest effective dose due to dependence potential, carefully monitoring benzo effects and patient response.[[3]](#article-18220.r3]
Chlordiazepoxide: For alcohol withdrawal, initiate with 50 to 100 mg, followed by up to 300 mg/day as needed, adjusted per CIWA-Ar protocol. Dosage should be titrated to achieve optimal benzo effects in managing withdrawal symptoms.[[21]](#article-18220.r21]
Clonazepam: Panic disorder initial dose is 0.5 mg daily, maintenance typically 1 mg daily. For seizure disorders, 0.5 mg three times daily, maximum 20 mg daily. Monitor closely for anticonvulsant benzo effects and adjust as needed.
Clobazam: For Lennox-Gastaut syndrome adjunct therapy, initial dose 10 mg for patients over 30 kg, increasing to 20 mg after one week, maintenance at 40 mg after two weeks. For patients under 30 kg, lower initial and maintenance doses are recommended. [5] Careful titration is needed to optimize benzo effects in seizure control.
Clorazepate: For focal (partial) onset seizures in patients over 12 years, start at 7.5 mg three times daily, maximum 90 mg daily.[[7]](#article-18220.r7] Monitor for seizure control and adjust dose to maximize anticonvulsant benzo effects.
Diazepam: ASAM 2020 guidelines for severe alcohol withdrawal (CIWA-Ar ≥19) recommend front-loading, e.g., 10 mg orally hourly if CIWA-Ar ≥10, or fixed schedule e.g., 20 mg orally every 2 hours for 3 doses.[[12]](#article-18220.r12] Rectal diazepam for febrile seizures: 0.5 mg/kg.[8][[22]](#article-18220.r22] Dosing strategies aim to rapidly achieve therapeutic benzo effects in acute withdrawal and seizure situations.
Estazolam: AASM recommends 1 to 2 mg at bedtime for sleep onset and maintenance insomnia.[[9]](#article-18220.r9] Dosage adjustments should be made to balance sedative benzo effects and next-day residual effects.
Flurazepam: For insomnia, 15 mg for women, 30 mg for men is recommended. Consider gender-based dosing for optimal sedative benzo effects.
Lorazepam: AES guidelines for convulsive status epilepticus: IV 0.1 mg/kg initial dose, maximum 4 mg, repeat at 3-5 minutes if needed.[[10]](#article-18220.r10] Rapid IV administration is crucial for achieving fast anticonvulsant benzo effects in emergencies.
Midazolam: For convulsive status epilepticus, 10 mg IM single dose preferred without IV access. Intranasal midazolam (0.2 mg/kg, max 10 mg) is usable pre-hospitally. For procedural sedation, dosing is patient-specific. [11][23][[24]](#article-18220.r24] Various routes allow for tailored administration based on clinical setting and desired benzo effects.
Oxazepam: For alcohol withdrawal, symptom-triggered dosing: 15 mg for CIWA-Ar 8-15, 30 mg for CIWA-Ar >15.[[12]](#article-18220.r12] Symptom-based dosing allows for individualized titration of benzo effects.
Quazepam: For sleep onset and maintenance insomnia, 7.5 mg/day at bedtime, may increase to 15 mg, but long half-life raises accumulation and daytime impairment concerns.[[13]](#article-18220.r13] Long duration of benzo effects requires careful consideration of daytime sedation.
Temazepam: AASM guidelines recommend 7.5 to 15 mg at bedtime for sleep onset and maintenance insomnia. Improves total sleep time, sleep latency, and sleep quality. CBT is recommended as initial treatment for chronic insomnia according to ACP guidelines.[9][[13]](#article-18220.r13] Benzodiazepines are often second-line to behavioral therapies for insomnia but provide effective sedative benzo effects.
Triazolam: For sleep-onset insomnia, 0.125 to 0.25 mg daily at bedtime, limit use to 4-8 weeks.[[12]](#article-18220.r12] Short-term use and low doses are recommended due to potential for dependence and rebound insomnia after cessation of benzo effects.
Remimazolam: Approved for short procedural sedation. [14] Dosing is weight-based and titrated to desired sedation level, capitalizing on rapid onset and offset of benzo effects.

Specific Patient Populations

Patient-specific factors significantly influence benzo effects and safety.

Hepatic impairment: Lorazepam and oxazepam metabolism is minimally affected by liver disease, making lorazepam a safer choice for alcohol withdrawal and hepatic impairment patients due to predictable benzo effects. Remimazolam should be used cautiously in severe hepatic impairment.[[25]](#article-18220.r25]
Renal impairment: Reduced clearance and plasma protein binding in renal impairment can increase unbound (active) benzodiazepine concentrations, potentially intensifying benzo effects. Lorazepam may be safer in ESRD, but diazepam accumulation risk exists. Lower starting doses and cautious titration are advised.[19][[26]](#article-18220.r26]
Pregnancy: Most benzodiazepines are former FDA pregnancy category D, indicating fetal risk. Diazepam and chlordiazepoxide may increase congenital malformations like cleft palate. Flurazepam and temazepam are pregnancy category X, linked to neonatal lethargy and skeletal development issues. Avoid benzodiazepines, especially in the first trimester.[27] NICE guidelines advise against benzodiazepines in pregnancy unless for severe anxiety, agitation, or seizures. Neonatal hypotonia and withdrawal are risks. Counseling about tapering before planned pregnancy is important.[28][[29]](#article-18220.r29]
Breastfeeding: Caution is needed in neonates and preterm infants due to hypotension risk, especially with opioids like fentanyl. Midazolam, lorazepam, and oxazepam may be used cautiously according to safety scoring systems. Avoid benzodiazepines during lactation unless clearly indicated.[30][31][[32]](#article-18220.r32]
Older patients: Beers Criteria flags benzodiazepines as potentially inappropriate for older adults due to increased sensitivity and reduced clearance, raising risks of cognitive impairment, falls, and fractures. However, reasonable use may be warranted for seizure disorders, alcohol withdrawal, periprocedural sedation, and severe generalized anxiety disorder.[[33]](#article-18220.r33] Start low and go slow approach is crucial to minimize adverse benzo effects in this population.
Pediatric patients: Lorazepam and diazepam IV are effective for seizures lasting over 5 minutes. Rectal diazepam, IM midazolam, intranasal midazolam, and buccal midazolam are also likely effective for managing acute seizures, leveraging their rapid anticonvulsant benzo effects.[[10]](#article-18220.r10]

Adverse Effects of Benzodiazepines

Benzodiazepine administration, while therapeutically beneficial, can lead to various adverse effects, stemming from their CNS depressant benzo effects. Common side effects include respiratory depression, respiratory arrest, drowsiness, confusion, headache, syncope, nausea, vomiting, diarrhea, and tremors.

In neonates, rare but serious adverse benzo effects (less than 1%) include laryngospasm and bronchospasm. Cardiovascular reactions may include ventricular arrhythmias, vasovagal syncope, bradycardia, or tachycardia. Gastrointestinal effects can include retching, nausea, vomiting, and excessive salivation. CNS and neuromuscular adverse effects may manifest as euphoria, hallucinations, ataxia, dizziness, seizure-like activity, and paresthesia.

Visual disturbances such as diplopia (“double vision”), cyclic eyelid movement, balance loss, and difficulty focusing can occur. Long-term benzodiazepine use is associated with cognitive impairment.[[34]](#article-18220.r34] Rare instances of cholestatic liver injury have been linked to benzodiazepines like alprazolam, clonazepam, diazepam, and flurazepam.[[35]](#article-18220.r35] Remimazolam can cause both hypertension and hypotension, necessitating blood pressure monitoring during procedures.[[36]](#article-18220.r36]

Drug-Drug Interactions

Drug interactions can significantly alter benzo effects, either enhancing or diminishing their therapeutic or adverse actions.

Lorazepam and oxazepam are metabolized by uridine diphosphate glucuronosyltransferases (UGTs). UGT inducers like carbamazepine, phenobarbital, phenytoin, and rifampin may accelerate metabolism, reducing efficacy and shortening the duration of benzo effects.[[7]](#article-18220.r7] Understanding these interactions is vital for managing concurrent medications.

Contraindications and Precautions

Warnings and Precautions

Contraindications for benzodiazepine use include known angle-closure glaucoma due to muscle relaxant benzo effects that can affect the iris sphincter pupillae muscle.[[40]](#article-18220.r40] Hypersensitivity reactions are also contraindications; anaphylaxis and angioedema have been reported.[[41]](#article-18220.r41] Remimazolam is contraindicated in patients with dextran 40 hypersensitivity.[[42]](#article-18220.r42]

Box Warning

A significant black box warning exists regarding concomitant use of benzodiazepines with opioids. This combination can lead to profound sedation, severe respiratory depression, coma, and death. Avoiding this combination is strongly recommended due to the synergistic CNS depressant benzo effects and opioid effects.[[43]](#article-18220.r43]

Monitoring Benzodiazepine Therapy

Monitoring is essential to ensure safe and effective use of benzodiazepines and to mitigate potential adverse benzo effects.

Benzodiazepines are CNS depressants, notably suppressing respiratory drive. Continuous monitoring of vital signs, especially blood pressure and respiratory rate, is crucial post-administration. Waveform capnography should be considered for enhanced respiratory monitoring.[[44]](#article-18220.r44] While benzodiazepines have a high therapeutic index, respiratory depression remains a critical concern, and rapid IV injection can induce respiratory arrest.[[44]](#article-18220.r44]

Alcohol withdrawal monitoring using the CIWA-Ar protocol guides benzodiazepine dose adjustments.[21] Patients on parenteral lorazepam or diazepam for alcohol withdrawal need monitoring for hyponatremia and metabolic acidosis due to propylene glycol in IV formulations.[[12]](#article-18220.r12] RASS monitoring is recommended for mechanically ventilated patients receiving benzodiazepines to prevent oversedation, aligning with SCCM guidelines for patient-centered sedation management.[23][24][[45]](#article-18220.r45]

Prescription drug monitoring programs can help healthcare professionals identify benzodiazepine misuse patterns, crucial given their DEA Schedule IV status. Flunitrazepam is an exception, carrying Schedule I penalties despite Schedule IV classification, highlighting the varying regulatory scrutiny based on abuse potential and benzo effects.[[46]](#article-18220.r46]

Benzodiazepine Toxicity and Overdose

Signs and Symptoms of Overdose

Benzodiazepine overdose manifests with extreme sedation, cognitive impairment, ataxia, and slurred speech. Respiratory depression is a critical, life-threatening concern. Cardiovascular effects such as hypotension and bradycardia further indicate systemic toxicity from excessive benzo effects.

Management of Overdose

Benzodiazepine overdose management prioritizes airway, breathing, and circulation, following AHA guidelines.[47] Flumazenil, a GABA-A receptor antagonist, reverses sedative benzo effects by competitive inhibition at the alpha-gamma subunit of the GABA-A receptor. However, flumazenil should be used cautiously as it can precipitate withdrawal seizures. Resedation after flumazenil wears off is a recognized risk.

Image: Diagram illustrating flumazenil’s mechanism as a benzodiazepine antagonist, reversing benzo effects in overdose.

Naloxone may be considered if opioid co-ingestion is suspected in patients with respiratory distress, using smaller initial doses (e.g., 0.05 mg) to avoid opioid withdrawal-induced vomiting, which poses aspiration risk in sedated patients.[48][[49]](#article-18220.r49] Activated charcoal is generally contraindicated in benzodiazepine overdose due to aspiration risk from altered mental status.[[50]](#article-18220.r50]

Recommendations for Overdose Management

AHA 2023 guidelines address cardiac arrest or toxicity from benzodiazepine poisoning. Isolated benzodiazepine poisoning rarely causes life-threatening hemodynamic instability or respiratory depression. Flumazenil, by reversing benzodiazepine-mediated sympathetic system suppression, can paradoxically lead to cardiac events like supraventricular tachycardia, ventricular dysrhythmias, and asystole, especially with co-existing arrhythmogenic drugs or hypoxia. In mixed overdoses, flumazenil may not fully reverse respiratory depression, and naloxone may be preferred if opioid co-ingestion is suspected.[[51]](#article-18220.r51]

Enhancing Healthcare Team Outcomes in Benzodiazepine Therapy

Benzodiazepines are frequently prescribed in both outpatient and inpatient settings, offering effective sedation and anxiolysis, but also carrying risks. All healthcare professionals involved in prescribing and managing these drugs must be acutely aware of adverse effects, misuse, abuse potential, and the risk of physical dependence associated with prolonged benzo effects. Benzodiazepines are DEA Schedule IV drugs, necessitating careful prescribing and monitoring. Pharmacists play a crucial role in medication reconciliation and identifying potential drug-drug interactions, informing prescribers of risks. Anesthesiologists and certified registered nurse anesthetists are vital in procedural sedation, ensuring safe administration and monitoring of benzo effects in controlled settings.

Nurses are essential for monitoring mechanically ventilated patients receiving benzodiazepines, assessing sedation levels and respiratory status. Neurologists should be consulted for specific benzodiazepine uses like clobazam for Lennox-Gastaut syndrome, guiding appropriate drug selection and management of benzo effects in complex neurological conditions. Intensivists are crucial when benzodiazepines are used for sedation in intensive care, balancing therapeutic benzo effects with minimizing risks of oversedation and prolonged ventilation. Emergency medicine physicians and nurses are first-line responders in benzodiazepine overdose, providing rapid stabilization and initial management of toxic benzo effects. Psychiatrists are vital for managing benzodiazepine use disorder, addressing dependence and withdrawal syndromes, and providing long-term care. Judicious prescribing is paramount, given the high abuse potential and regulatory scrutiny on inappropriate benzodiazepine prescriptions.[52][[53]](#article-18220.r53]

Interprofessional collaboration among clinicians, specialists, pharmacists, and nurses is essential for optimizing benzodiazepine therapy and patient outcomes. Team-based models involving clinical pharmacists and primary care physicians for anxiety and insomnia management can improve therapy optimization and minimize risks associated with benzodiazepine use, ensuring comprehensive management of benzo effects and patient safety.[[54]](#article-18220.r54]

Review Questions

[Link to Review Questions] (https://www.statpearls.com/account/trialuserreg/?articleid=18220&utm_source=pubmed&utm_campaign=reviews&utm_content=18220)

References

1.Maust DT, Solway E, Clark SJ, Kirch M, Singer DC, Malani P. Prescription and Nonprescription Sleep Product Use Among Older Adults in the United States. Am J Geriatr Psychiatry. 2019 Jan;27(1):32-41. [PubMed: 30409547]

2.Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and Correlates of Benzodiazepine Use, Misuse, and Use Disorders Among Adults in the United States. J Clin Psychiatry. 2018 Oct 16;79(6) [PMC free article: PMC10309967] [PubMed: 30403446]

3.Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front Psychiatry. 2020;11:595584. [PMC free article: PMC7786299] [PubMed: 33424664]

4.March KL, Twilla JD, Reaves AB, Self TH, Slayton MM, Bergeron JB, Sakaan SA. Lorazepam versus chlordiazepoxide for the treatment of alcohol withdrawal syndrome and prevention of delirium tremens in general medicine ward patients. Alcohol. 2019 Dec;81:56-60. [PubMed: 31176787]

5.Isojarvi J, Gidal BE, Chung S, Wechsler RT. Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome. Epilepsy Behav. 2018 Jan;78:149-154. [PubMed: 29202277]

6.Brigo F, Igwe SC, Bragazzi NL, Lattanzi S. Clonazepam monotherapy for treating people with newly diagnosed epilepsy. Cochrane Database Syst Rev. 2019 Nov 19;2019(11) [PMC free article: PMC6863099] [PubMed: 31742671]

7.Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. [PubMed: 18384456]

8.Chiang LM, Wang HS, Shen HH, Deng ST, Tseng CH, Chen YI, Chou ML, Hung PC, Lin KL. Rectal diazepam solution is as good as rectal administration of intravenous diazepam in the first-aid cessation of seizures in children with intractable epilepsy. Pediatr Neonatol. 2011 Feb;52(1):30-3. [PubMed: 21385654]

9.Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017 Feb 15;13(2):307-349. [PMC free article: PMC5263087] [PubMed: 27998379]

10.Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016 Jan-Feb;16(1):48-61. [PMC free article: PMC4749120] [PubMed: 26900382]

11.Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-e873. [PubMed: 30113379]

12.The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. J Addict Med. 2020 May/Jun;14(3S Suppl 1):1-72. [PubMed: 32511109]

13.Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD., Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016 Jul 19;165(2):125-33. [PubMed: 27136449]

14.Kilpatrick GJ. Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent. Front Pharmacol. 2021;12:690875. [PMC free article: PMC8329483] [PubMed: 34354587]

15.Poisbeau P, Gazzo G, Calvel L. Anxiolytics targeting GABAA receptors: Insights on etifoxine. World J Biol Psychiatry. 2018;19(sup1):S36-S45. [PubMed: 30204559]

16.Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012 Nov 23;287(48):40224-31. [PMC free article: PMC3504738] [PubMed: 23038269]

17.Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013 Summer;13(2):214-23. [PMC free article: PMC3684331] [PubMed: 23789008]

18.Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol. 2020 Aug;33(4):506-511. [PubMed: 32530890]

19.Wilcock A, Charlesworth S, Twycross R, Waddington A, Worthington O, Murtagh FEM, Beavis J, King S, Mihalyo M, Kotlinska-Lemieszek A. Prescribing Non-Opioid Drugs in End-Stage Kidney Disease. J Pain Symptom Manage. 2017 Nov;54(5):776-787. [PubMed: 28843456]

20.Borrelli EP, Bratberg J, Hallowell BD, Greaney ML, Kogut SJ. Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018. J Manag Care Spec Pharm. 2022 Jan;28(1):58-68. [PMC free article: PMC10373022] [PubMed: 34949119]

21.Melkonian A, Patel R, Magh A, Ferm S, Hwang C. Assessment of a Hospital-Wide CIWA-Ar Protocol for Management of Alcohol Withdrawal Syndrome. Mayo Clin Proc Innov Qual Outcomes. 2019 Sep;3(3):344-349. [PMC free article: PMC6713876] [PubMed: 31485573]

22.Ghazavi M, Nasiri J, Yaghini O, Soltani R. Oral Diazepam in Febrile Seizures Following Acellular Pertussis Vaccination. Adv Biomed Res. 2019;8:29. [PMC free article: PMC6507365] [PubMed: 31114769]

23.Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000 May 18;342(20):1471-7. [PubMed: 10816184]

24.Hughes CG, Mailloux PT, Devlin JW, Swan JT, Sanders RD, Anzueto A, Jackson JC, Hoskins AS, Pun BT, Orun OM, Raman R, Stollings JL, Kiehl AL, Duprey MS, Bui LN, O’Neal HR, Snyder A, Gropper MA, Guntupalli KK, Stashenko GJ, Patel MB, Brummel NE, Girard TD, Dittus RS, Bernard GR, Ely EW, Pandharipande PP., MENDS2 Study Investigators. Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis. N Engl J Med. 2021 Apr 15;384(15):1424-1436. [PMC free article: PMC8162695] [PubMed: 33528922]

25.Gershkovich P, Wasan KM, Ribeyre C, Ibrahim F, McNeill JH. Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome. Drugs Context. 2015;4:212287. [PMC free article: PMC4544271] [PubMed: 26322116]

26.Wyne A, Rai R, Cuerden M, Clark WF, Suri RS. Opioid and benzodiazepine use in end-stage renal disease: a systematic review. Clin J Am Soc Nephrol. 2011 Feb;6(2):326-33. [PMC free article: PMC3052223] [PubMed: 21071517]

27.Creeley CE, Denton LK. Use of Prescribed Psychotropics during Pregnancy: A Systematic Review of Pregnancy, Neonatal, and Childhood Outcomes. Brain Sci. 2019 Sep 14;9(9) [PMC free article: PMC6770670] [PubMed: 31540060]

28.Antenatal and postnatal mental health: clinical management and service guidance. National Institute for Health and Care Excellence (NICE); London: Apr, 2018. [PubMed: 31990493]

29.Shyken JM, Babbar S, Babbar S, Forinash A. Benzodiazepines in Pregnancy. Clin Obstet Gynecol. 2019 Mar;62(1):156-167. [PubMed: 30628916]

30.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jan 15, 2024. Lorazepam. [PubMed: 30000290]

31.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Oct 15, 2024. Midazolam. [PubMed: 30000294]

32.Uguz F. A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation. 2021 Jan-Feb 01Am J Ther. 28(1):e118-e126. [PubMed: 30601177]

33.By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. [PubMed: 37139824]

34.Crowe SF, Stranks EK. The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis. Arch Clin Neuropsychol. 2018 Nov 01;33(7):901-911. [PubMed: 29244060]

35.LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jan 24, 2017. Benzodiazepines. [PMC free article: PMC547852] [PubMed: 31643621]

36.Lee A, Shirley M. Remimazolam: A Review in Procedural Sedation. Drugs. 2021 Jul;81(10):1193-1201. [PubMed: 34196946]

37.Weaver MF. Prescription Sedative Misuse and Abuse. Yale J Biol Med. 2015 Sep;88(3):247-56. [PMC free article: PMC4553644] [PubMed: 26339207]

38.Boulenc X, Nicolas O, Hermabessière S, Zobouyan I, Martin V, Donazzolo Y, Ollier C. CYP3A4-based drug-drug interaction: CYP3A4 substrates’ pharmacokinetic properties and ketoconazole dose regimen effect. Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):45-54. [PubMed: 25374256]

39.Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 Jan;38(1):41-57. [PubMed: 10668858]

40.Park MY, Kim WJ, Lee E, Kim C, Son SJ, Yoon JS, Kim W, Namkoong K. Association between use of benzodiazepines and occurrence of acute angle-closure glaucoma in the elderly: A population-based study. J Psychosom Res. 2019 Jul;122:1-5. [PubMed: 31126405]

41.Haybarger E, Young AS, Giovannitti JA. Benzodiazepine Allergy With Anesthesia Administration: A Review of Current Literature. Anesth Prog. 2016 Fall;63(3):160-7. [PMC free article: PMC5011959] [PubMed: 27585420]

42.Shiratori T, Sato A, Fukuzawa M, Kondo N, Tanno S. Severe Dextran-Induced Anaphylactic Shock during Induction of Hypertension-Hypervolemia-Hemodilution Therapy following Subarachnoid Hemorrhage. Case Rep Crit Care. 2015;2015:967560. [PMC free article: PMC4480245] [PubMed: 26171255]

43.Aschenbrenner DS. Stronger Boxed Warning for Benzodiazepines. Am J Nurs. 2021 Mar 01;121(3):22-23. [PubMed: 33625005]

44.Hatlestad D. Capnography in sedation and pain management. Emerg Med Serv. 2005 Mar;34(3):65-9. [PubMed: 15839539]

45.Medlej K. Calculated decisions: Richmond Agitation-Sedation Scale (RASS). Emerg Med Pract. 2021 Mar 15;23(Suppl 3):CD3-CD4. [PubMed: 33729737]

46.Liang D, Guo H, Shi Y. Mandatory use of prescription drug monitoring program and benzodiazepine prescribing among U.S. Medicaid enrollees. Subst Abus. 2021;42(3):294-301. [PMC free article: PMC7202951] [PubMed: 31697195]

47.Panchal AR, Bartos JA, Cabañas JG, Donnino MW, Drennan IR, Hirsch KG, Kudenchuk PJ, Kurz MC, Lavonas EJ, Morley PT, O’Neil BJ, Peberdy MA, Rittenberger JC, Rodriguez AJ, Sawyer KN, Berg KM., Adult Basic and Advanced Life Support Writing Group. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020 Oct 20;142(16_suppl_2):S366-S468. [PubMed: 33081529]

48.Gallo AT, Hulse G. Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data. J Psychopharmacol. 2021 Mar;35(3):211-220. [PubMed: 33426982]

49.Sivilotti ML. Flumazenil, naloxone and the ‘coma cocktail’. Br J Clin Pharmacol. 2016 Mar;81(3):428-36. [PMC free article: PMC4767210] [PubMed: 26469689]

50.Zellner T, Prasa D, Färber E, Hoffmann-Walbeck P, Genser D, Eyer F. The Use of Activated Charcoal to Treat Intoxications. Dtsch Arztebl Int. 2019 May 03;116(18):311-317. [PMC free article: PMC6620762] [PubMed: 31219028]

51.Lavonas EJ, Akpunonu PD, Arens AM, Babu KM, Cao D, Hoffman RS, Hoyte CO, Mazer-Amirshahi ME, Stolbach A, St-Onge M, Thompson TM, Wang GS, Hoover AV, Drennan IR., American Heart Association. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2023 Oct 17;148(16):e149-e184. [PubMed: 37721023]

52.Jørgensen MB, Osler M. Should benzodiazepines be avoided? Acta Psychiatr Scand. 2018 Aug;138(2):89-90. [PubMed: 30398297]

53.Revet A, Yrondi A, Montastruc F. [Good practices in prescribing benzodiazepines]. Presse Med. 2018 Oct;47(10):872-877. [PubMed: 30385184]

54.Furbish SML, Kroehl ME, Loeb DF, Lam HM, Lewis CL, Nelson J, Chow Z, Trinkley KE. A Pharmacist-Physician Collaboration to Optimize Benzodiazepine Use for Anxiety and Sleep Symptom Control in Primary Care. J Pharm Pract. 2017 Aug;30(4):425-433. [PMC free article: PMC5511764] [PubMed: 27480874]

Disclosure: Connor Bounds declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.